ID   HCT 15
AC   CVCL_0292
SY   HCT-15; HCT15
DR   BTO; BTO:0002201
DR   CLO; CLO_0003666
DR   EFO; EFO_0002188
DR   MCCL; MCC:0000182
DR   CLDB; cl1576
DR   CLDB; cl4985
DR   AddexBio; C0009010/381
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ATCC; CCL-225
DR   BCRC; 60539
DR   BioSample; SAMN01821556
DR   BioSample; SAMN01821630
DR   BioSample; SAMN03471553
DR   BioSample; SAMN10987770
DR   CCLE; HCT15_LARGE_INTESTINE
DR   CCRID; 3111C0001CCC000247
DR   CCRID; 3131C0001000700133
DR   CCTCC; GDC0250
DR   Cell_Model_Passport; SIDM00789
DR   ChEMBL-Cells; CHEMBL3307945
DR   ChEMBL-Targets; CHEMBL612263
DR   CLS; 300229/p23303_HCT-15.html
DR   ColonAtlas; HCT15
DR   Cosmic; 711261
DR   Cosmic; 873700
DR   Cosmic; 875902
DR   Cosmic; 887222
DR   Cosmic; 897458
DR   Cosmic; 905007
DR   Cosmic; 905937
DR   Cosmic; 913889
DR   Cosmic; 934567
DR   Cosmic; 947354
DR   Cosmic; 995403
DR   Cosmic; 1044258
DR   Cosmic; 1057756
DR   Cosmic; 1066206
DR   Cosmic; 1092601
DR   Cosmic; 1122324
DR   Cosmic; 1132569
DR   Cosmic; 1175841
DR   Cosmic; 1184092
DR   Cosmic; 1187307
DR   Cosmic; 1218878
DR   Cosmic; 1305354
DR   Cosmic; 1310950
DR   Cosmic; 1312338
DR   Cosmic; 1436020
DR   Cosmic; 1466814
DR   Cosmic; 1479592
DR   Cosmic; 1526922
DR   Cosmic; 1609492
DR   Cosmic; 1676747
DR   Cosmic; 1708403
DR   Cosmic; 1995438
DR   Cosmic; 1998443
DR   Cosmic; 2036655
DR   Cosmic; 2156942
DR   Cosmic; 2301979
DR   Cosmic; 2664053
DR   Cosmic; 2727470
DR   Cosmic-CLP; 905937
DR   DepMap; ACH-000997
DR   DSMZ; ACC-357
DR   ECACC; 91030712
DR   GDSC; 905937
DR   GEO; GSM2129
DR   GEO; GSM50189
DR   GEO; GSM50253
DR   GEO; GSM206502
DR   GEO; GSM274763
DR   GEO; GSM274764
DR   GEO; GSM481406
DR   GEO; GSM513816
DR   GEO; GSM514293
DR   GEO; GSM741257
DR   GEO; GSM750792
DR   GEO; GSM784011
DR   GEO; GSM799332
DR   GEO; GSM799395
DR   GEO; GSM846356
DR   GEO; GSM844554
DR   GEO; GSM887063
DR   GEO; GSM888133
DR   GEO; GSM1153402
DR   GEO; GSM1181251
DR   GEO; GSM1181363
DR   GEO; GSM1346875
DR   GEO; GSM1374519
DR   GEO; GSM1374520
DR   GEO; GSM1374521
DR   GEO; GSM1374522
DR   GEO; GSM1448178
DR   GEO; GSM1669869
DR   GEO; GSM2124665
DR   GEO; GSM2550002
DR   ICLC; HTL00001
DR   IGRhCellID; HCT15
DR   KCB; KCB 201197YJ
DR   KCLB; 10225
DR   LiGeA; CCLE_761
DR   LINCS_LDP; LCL-1178
DR   Lonza; 492
DR   MetaboLights; MTBLS227
DR   NCI-DTP; HCT-15
DR   PRIDE; PXD005235
DR   PRIDE; PXD005942
DR   RCB; RCB1958
DR   SKY/M-FISH/CGH; 2786
DR   TKG; TKG 0504
DR   TOKU-E; 1423
DR   Wikidata; Q54882006
RX   PubMed=427742;
RX   PubMed=2041050;
RX   PubMed=7139607;
RX   PubMed=7247963;
RX   PubMed=8197130;
RX   PubMed=9000147;
RX   PubMed=9000572;
RX   PubMed=9809040;
RX   PubMed=10700174;
RX   PubMed=10737795;
RX   PubMed=11314036;
RX   PubMed=11414198;
RX   PubMed=11526487;
RX   PubMed=12584437;
RX   PubMed=15748285;
RX   PubMed=15900046;
RX   PubMed=16854228;
RX   PubMed=17088437;
RX   PubMed=19372543;
RX   PubMed=20164919;
RX   PubMed=20215515;
RX   PubMed=20570890;
RX   PubMed=20606684;
RX   PubMed=22336246;
RX   PubMed=22384151;
RX   PubMed=22460905;
RX   PubMed=22628656;
RX   PubMed=23856246;
RX   PubMed=23933261;
RX   PubMed=24042735;
RX   PubMed=24279929;
RX   PubMed=24670534;
RX   PubMed=24755471;
RX   PubMed=25485619;
RX   PubMed=25926053;
RX   PubMed=26169745;
RX   PubMed=26537799;
RX   PubMed=27377824;
RX   PubMed=27397505;
RX   PubMed=27807467;
RX   PubMed=28192450;
RX   PubMed=28196595;
RX   PubMed=28683746;
RX   PubMed=28854368;
RX   PubMed=29444439;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   https://dtp.cancer.gov/discovery_development/nci-60/cell_list.htm
WW   https://strap.nci.nih.gov/celline_detail.php?sample_id=20
WW   http://www.pawefish.path.cam.ac.uk/ColonCellLineDescriptions/HCT15.html
WW   http://tcpaportal.org/mclp/
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: COSMIC cell lines project.
CC   Part of: JFCR39 cancer cell line panel.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   Part of: NCI RAS program mutant KRAS cell line panel.
CC   Part of: NCI-60 cancer cell line panel.
CC   Part of: PI3K genetic alteration cell panel (ATCC TCP-1028).
CC   Part of: RAS genetic alteration cell panel (ATCC TCP-1031).
CC   Doubling time: 19 hours (PubMed=427742); ~20 hours (PubMed=7139607); 20.6 hours (NCI-DTP); ~20-25 hours (DSMZ).
CC   HLA typing: A*02,24; B*08,35:01:01; C*04,07; DPB1*01:01:01,04:01; DQB1*02,05:03:01; DRB1*03,14 (PubMed=15748285).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=11526487; PubMed=24042735; PubMed=25926053; PubMed=28683746; PubMed=31068700; Sanger).
CC   Sequence variation: Homozygous for APC p.Ile1417fs*2 (c.4248delC) (PubMed=17088437; PubMed=24755471).
CC   Sequence variation: Heterozygous for APC p.Arg2166Ter (c.6496C>T) (PubMed=17088437; PubMed=24755471).
CC   Sequence variation: APC p.Arg727Met (c.2180G>T), p.Lys993Asn (c.2979G>T), p.Ile1417fs*2 (c.4248delC) and p.Arg2166Ter (c.6496C>T) (PubMed=24755471).
CC   Sequence variation: Heterozygous for B2M c.68-1G>T; splice acceptor mutation and p.Tyr30Ter (c.90C>A) (PubMed=8197130).
CC   Sequence variation: Heterozygous for BRCA2 p.Cys1200fs*1 and p.Asn1784Hisfs*7 (c.5350_5351delAA) (PubMed=17088437).
CC   Sequence variation: Heterozygous for KRAS p.Gly13Asp (c.38G>A) (PubMed=17088437; PubMed=20570890; PubMed=24755471; PubMed=28683746; ATCC).
CC   Sequence variation: Heterozygous for PIK3CA p.Glu545Lys (c.1633G>A) (PubMed=17088437; PubMed=20570890; PubMed=24755471; PubMed=28683746).
CC   Sequence variation: PIK3CA p.Asp549Asn (c.1645G>A) (PubMed=24755471).
CC   Sequence variation: Heterozygous for TP53 p.Ser241Phe (c.722C>T) (PubMed=15900046; PubMed=17088437; PubMed=28683746).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Fluorescence phenotype profiling.
CC   Omics: lncRNA expression profiling.
CC   Omics: Metabolome analysis.
CC   Omics: miRNA expression profiling.
CC   Omics: N-glycan profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=2.68%; Native American=0%; East Asian, North=5.84%; East Asian, South=0%; South Asian=0%; European, North=49.17%; European, South=42.32% (PubMed=30894373).
CC   Misspelling: HTC-15; Occasionally.
CC   Misspelling: HTC15; Occasionally.
CC   Discontinued: RCB; RCB1958; true.
ST   Source(s): AddexBio; ATCC; Cosmic-CLP; DSMZ; ECACC; KCLB; PubMed=11416159; PubMed=19372543; PubMed=25877200; PubMed=25926053; TKG
ST   Amelogenin: X,Y
ST   CSF1PO: 12
ST   D13S317: 8,11
ST   D16S539: 12,13
ST   D18S51: 11,17
ST   D19S433: 14,16
ST   D21S11: 29,32.2
ST   D2S1338: 17,25
ST   D3S1358: 17
ST   D5S818: 13
ST   D7S820: 10,12
ST   D8S1179: 15
ST   FGA: 22
ST   Penta D: 9,14
ST   Penta E: 7,14
ST   TH01: 7,9.3
ST   TPOX: 8,11
ST   vWA: 18,19
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_3449 ! __Parent_cell_line_of_DLD-1/HCT 8/HCT 15/HRT-18
SX   Male
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-07-19; Version: 30
//
RX   PubMed=427742;
RA   Dexter D.L., Barbosa J.A., Calabresi P.;
RT   "N,N-dimethylformamide-induced alteration of cell culture
RT   characteristics and loss of tumorigenicity in cultured human colon
RT   carcinoma cells.";
RL   Cancer Res. 39:1020-1025(1979).
//
RX   PubMed=2041050; DOI=10.1093/jnci/83.11.757;
RA   Monks A., Scudiero D.A., Skehan P., Shoemaker R.H., Paull K., Vistica D.T.,
RA   Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M.,
RA   Campbell H., Mayo J., Boyd M.;
RT   "Feasibility of a high-flux anticancer drug screen using a diverse
RT   panel of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 83:757-766(1991).
//
RX   PubMed=7139607;
RA   Dexter D.L., Spremulli E.N., Matook G.M., Diamond I., Calabresi P.;
RT   "Inhibition of the growth of human colon cancer xenografts by polar
RT   solvents.";
RL   Cancer Res. 42:5018-5022(1982).
//
RX   PubMed=7247963; DOI=10.1016/0006-2952(81)90167-2;
RA   Crabtree G.W., Dexter D.L., Stoeckler J.D., Savarese T.M., Ghoda L.Y.,
RA   Rogler-Brown T.L., Calabresi P., Parks R.E. Jr.;
RT   "Activities of purine-metabolizing enzymes in human colon carcinoma
RT   cell lines and xenograft tumors.";
RL   Biochem. Pharmacol. 30:793-798(1981).
//
RX   PubMed=8197130; DOI=10.1073/pnas.91.11.4751;
RA   Bicknell D.C., Rowan A., Bodmer W.F.;
RT   "Beta 2-microglobulin gene mutations: a study of established
RT   colorectal cell lines and fresh tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:4751-4755(1994).
//
RX   PubMed=9000147;
RA   Cottu P.H., Muzeau F., Estreicher A., Flejou J.-F., Iggo R.D.,
RA   Thomas G., Hamelin R.;
RT   "Inverse correlation between RER+ status and p53 mutation in
RT   colorectal cancer cell lines.";
RL   Oncogene 13:2727-2730(1996).
//
RX   PubMed=9000572;
RA   Hoang J.-M., Cottu P.H., Thuille B., Salmon R.J., Thomas G.,
RA   Hamelin R.;
RT   "BAT-26, an indicator of the replication error phenotype in colorectal
RT   cancers and cell lines.";
RL   Cancer Res. 57:300-303(1997).
//
RX   PubMed=9809040; DOI=10.1016/S0165-4608(98)00081-8;
RA   Vermeulen S.J., Chen T.-R., Speleman F., Nollet F., van Roy F.M.,
RA   Mareel M.M.;
RT   "Did the four human cancer cell lines DLD-1, HCT-15, HCT-8, and HRT-18
RT   originate from one and the same patient?";
RL   Cancer Genet. Cytogenet. 107:76-79(1998).
//
RX   PubMed=10700174; DOI=10.1038/73432;
RA   Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T.,
RA   Iyer V., Jeffrey S.S., van de Rijn M., Waltham M., Pergamenschikov A.,
RA   Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N.,
RA   Botstein D., Brown P.O.;
RT   "Systematic variation in gene expression patterns in human cancer cell
RT   lines.";
RL   Nat. Genet. 24:227-235(2000).
//
RX   PubMed=10737795; DOI=10.1073/pnas.97.7.3352;
RA   Rowan A.J., Lamlum H., Ilyas M., Wheeler J., Straub J.,
RA   Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.;
RT   "APC mutations in sporadic colorectal tumors: a mutational 'hotspot'
RT   and interdependence of the 'two hits'.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).
//
RX   PubMed=11314036; DOI=10.1038/sj.onc.1204211;
RA   Forgacs E., Wren J.D., Kamibayashi C., Kondo M., Xu X.L.,
RA   Markowitz S.D., Tomlinson G.E., Muller C.Y., Gazdar A.F., Garner H.R.,
RA   Minna J.D.;
RT   "Searching for microsatellite mutations in coding regions in lung,
RT   breast, ovarian and colorectal cancers.";
RL   Oncogene 20:1005-1009(2001).
//
RX   PubMed=11414198; DOI=10.1007/s004320000207;
RA   Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H.,
RA   Wolf E., Gabius H.J.;
RT   "Comprehensive galectin fingerprinting in a panel of 61 human tumor
RT   cell lines by RT-PCR and its implications for diagnostic and
RT   therapeutic procedures.";
RL   J. Cancer Res. Clin. Oncol. 127:375-386(2001).
//
RX   PubMed=11526487; DOI=10.1038/sj.onc.1204611;
RA   Gayet J., Zhou X.-P., Duval A., Rolland S., Hoang J.-M., Cottu P.H.,
RA   Hamelin R.;
RT   "Extensive characterization of genetic alterations in a series of
RT   human colorectal cancer cell lines.";
RL   Oncogene 20:5025-5032(2001).
//
RX   PubMed=12584437; DOI=10.1159/000068544;
RA   Melcher R., Koehler S., Steinlein C., Schmid M., Mueller C.R.,
RA   Luehrs H., Menzel T., Scheppach W., Moerk H., Scheurlen M.,
RA   Koehrle J., Al-Taie O.;
RT   "Spectral karyotype analysis of colon cancer cell lines of the tumor
RT   suppressor and mutator pathway.";
RL   Cytogenet. Genome Res. 98:22-28(2002).
//
RX   PubMed=15748285; DOI=10.1186/1479-5876-3-11;
RA   Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L.,
RA   Morse H.C. III, Stroncek D., Marincola F.M.;
RT   "HLA class I and II genotype of the NCI-60 cell lines.";
RL   J. Transl. Med. 3:11-11(2005).
//
RX   PubMed=15900046; DOI=10.1093/jnci/dji133;
RA   Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y.,
RA   Yamazaki K., Hamada J., Tada M., Moriuchi T., Ishikawa Y., Kato Y.,
RA   Tomoda H., Yamori T., Tsuruo T.;
RT   "p53-defective tumors with a functional apoptosome-mediated pathway: a
RT   new therapeutic target.";
RL   J. Natl. Cancer Inst. 97:765-777(2005).
//
RX   PubMed=16854228; DOI=10.1186/1476-4598-5-29;
RA   Bandres E., Cubedo E., Agirre X., Malumbres R., Zarate R., Ramirez N.,
RA   Abajo A., Navarro A., Moreno I., Monzo M., Garcia-Foncillas J.;
RT   "Identification by real-time PCR of 13 mature microRNAs differentially
RT   expressed in colorectal cancer and non-tumoral tissues.";
RL   Mol. Cancer 5:29-29(2006).
//
RX   PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433;
RA   Ikediobi O.N., Davies H., Bignell G.R., Edkins S., Stevens C.,
RA   O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L.,
RA   Buck G., Butler A., Clements J., Cole J., Dicks E., Forbes S.,
RA   Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C.,
RA   Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A.,
RA   Mironenko T., Parker A., Perry J., Raine K., Richardson D.,
RA   Shepherd R., Small A., Smith R., Solomon H., Stephens P., Teague J.W.,
RA   Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R.;
RT   "Mutation analysis of 24 known cancer genes in the NCI-60 cell line
RT   set.";
RL   Mol. Cancer Ther. 5:2606-2612(2006).
//
RX   PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921;
RA   Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y.,
RA   Chanock S.J., Weinstein J.N.;
RT   "DNA fingerprinting of the NCI-60 cell line panel.";
RL   Mol. Cancer Ther. 8:713-724(2009).
//
RX   PubMed=20164919; DOI=10.1038/nature08768;
RA   Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S.,
RA   Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S.,
RA   Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T.,
RA   Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.;
RT   "Signatures of mutation and selection in the cancer genome.";
RL   Nature 463:893-898(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=20570890; DOI=10.1158/0008-5472.CAN-10-0192;
RA   Janakiraman M., Vakiani E., Zeng Z., Pratilas C.A., Taylor B.S.,
RA   Chitale D., Halilovic E., Wilson M., Huberman K., Ricarte Filho J.C.,
RA   Persaud Y., Levine D.A., Fagin J.A., Jhanwar S.C., Mariadason J.M.,
RA   Lash A., Ladanyi M., Saltz L.B., Heguy A., Paty P.B., Solit D.B.;
RT   "Genomic and biological characterization of exon 4 KRAS mutations in
RT   human cancer.";
RL   Cancer Res. 70:5901-5911(2010).
//
RX   PubMed=20606684; DOI=10.1038/sj.bjc.6605780;
RA   Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.;
RT   "5-fluorouracil response in a large panel of colorectal cancer cell
RT   lines is associated with mismatch repair deficiency.";
RL   Br. J. Cancer 103:340-346(2010).
//
RX   PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017;
RA   Kong D., Yamori T.;
RT   "JFCR39, a panel of 39 human cancer cell lines, and its application in
RT   the discovery and development of anticancer drugs.";
RL   Bioorg. Med. Chem. 20:1947-1951(2012).
//
RX   PubMed=22384151; DOI=10.1371/journal.pone.0032096;
RA   Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H.,
RA   Yoon C.N., Chang Y.-T.;
RT   "Identification of cancer cell-line origins using fluorescence
RT   image-based phenomic screening.";
RL   PLoS ONE 7:E32096-E32096(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22628656; DOI=10.1126/science.1218595;
RA   Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L.,
RA   Kafri R., Kirschner M.W., Clish C.B., Mootha V.K.;
RT   "Metabolite profiling identifies a key role for glycine in rapid
RT   cancer cell proliferation.";
RL   Science 336:1040-1044(2012).
//
RX   PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342;
RA   Abaan O.D., Polley E.C., Davis S.R., Zhu Y.J., Bilke S., Walker R.L.,
RA   Pineda M., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L.,
RA   Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S.;
RT   "The exomes of the NCI-60 panel: a genomic resource for cancer biology
RT   and systems pharmacology.";
RL   Cancer Res. 73:4372-4382(2013).
//
RX   PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018;
RA   Moghaddas Gholami A., Hahne H., Wu Z., Auer F.J., Meng C., Wilhelm M.,
RA   Kuster B.;
RT   "Global proteome analysis of the NCI-60 cell line panel.";
RL   Cell Rep. 4:609-620(2013).
//
RX   PubMed=24042735; DOI=10.1038/oncsis.2013.35;
RA   Ahmed D., Eide P.W., Eilertsen I.A., Danielsen S.A., Eknaes M.,
RA   Hektoen M., Lind G.E., Lothe R.A.;
RT   "Epigenetic and genetic features of 24 colon cancer cell lines.";
RL   Oncogenesis 2:E71-E71(2013).
//
RX   PubMed=24279929; DOI=10.1186/2049-3002-1-20;
RA   Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R.,
RA   Hirshfield K.M., Oltvai Z.N., Vazquez A.;
RT   "The metabolic demands of cancer cells are coupled to their size and
RT   protein synthesis rates.";
RL   Cancer Metab. 1:20-20(2013).
//
RX   PubMed=24670534; DOI=10.1371/journal.pone.0092047;
RA   Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C.;
RT   "High resolution copy number variation data in the NCI-60 cancer cell
RT   lines from whole genome microarrays accessible through CellMiner.";
RL   PLoS ONE 9:E92047-E92047(2014).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002-7002(2015).
//
RX   PubMed=26169745; DOI=10.1186/s12967-015-0576-z;
RA   Halama A., Guerrouahen B.S., Pasquier J., Diboun I., Karoly E.D.,
RA   Suhre K., Rafii A.;
RT   "Metabolic signatures differentiate ovarian from colon cancer cell
RT   lines.";
RL   J. Transl. Med. 13:223-223(2015).
//
RX   PubMed=26537799; DOI=10.1074/mcp.M115.051235;
RA   Holst S., Deuss A.J.M., van Pelt G.W., van Vliet S.J.,
RA   Garcia-Vallejo J.J., Koeleman C.A.M., Deelder A.M., Mesker W.E.,
RA   Tollenaar R.A., Rombouts Y., Wuhrer M.;
RT   "N-glycosylation profiling of colorectal cancer cell lines reveals
RT   association of fucosylation with differentiation and caudal type
RT   homebox 1 (CDX1)/villin mRNA expression.";
RL   Mol. Cell. Proteomics 15:124-140(2016).
//
RX   PubMed=27377824; DOI=10.1038/sdata.2016.52;
RA   Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J.,
RA   Vandesompele J.;
RT   "Long non-coding RNA expression profiling in the NCI60 cancer cell
RT   line panel using high-throughput RT-qPCR.";
RL   Sci. Data 3:160052-160052(2016).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M.,
RA   Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M.,
RA   Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A.,
RA   Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=27807467; DOI=10.1186/s13100-016-0078-4;
RA   Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J.,
RA   Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H.;
RT   "A map of mobile DNA insertions in the NCI-60 human cancer cell
RT   panel.";
RL   Mob. DNA 7:20-20(2016).
//
RX   PubMed=28192450; DOI=10.1371/journal.pone.0171435;
RA   Fasterius E., Raso C., Kennedy S., Rauch N., Lundin P., Kolch W.,
RA   Uhlen M., Al-Khalili Szigyarto C.;
RT   "A novel RNA sequencing data analysis method for cell line
RT   authentication.";
RL   PLoS ONE 12:E0171435-E0171435(2017).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28683746; DOI=10.1186/s12943-017-0691-y;
RA   Berg K.C.G., Eide P.W., Eilertsen I.A., Johannessen B., Bruun J.,
RA   Danielsen S.A., Bjornslett M., Meza-Zepeda L.A., Eknaes M., Lind G.E.,
RA   Myklebost O., Skotheim R.I., Sveen A., Lothe R.A.;
RT   "Multi-omics of 34 colorectal cancer cell lines - a resource for
RT   biomedical studies.";
RL   Mol. Cancer 16:116-116(2017).
//
RX   PubMed=28854368; DOI=10.1016/j.celrep.2017.08.010;
RA   Roumeliotis T.I., Williams S.P., Goncalves E., Alsinet C.,
RA   Del Castillo Velasco-Herrera M., Aben N., Ghavidel F.Z., Michaut M.,
RA   Schubert M., Price S., Wright J.C., Yu L., Yang M., Dienstmann R.,
RA   Guinney J., Beltrao P., Brazma A., Pardo M., Stegle O., Adams D.J.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.;
RT   "Genomic determinants of protein abundance variation in colorectal
RT   cancer cells.";
RL   Cell Rep. 20:2201-2214(2017).
//
RX   PubMed=29444439; DOI=10.1016/j.celrep.2018.01.051;
RA   Yuan T.L., Amzallag A., Bagni R., Yi M., Afghani S., Burgan W.,
RA   Fer N., Strathern L.A., Powell K., Smith B., Waters A.M., Drubin D.,
RA   Thomson T., Liao R., Greninger P., Stein G.T., Murchie E., Cortez E.,
RA   Egan R.K., Procter L., Bess M., Cheng K.T., Lee C.-S., Lee L.C.,
RA   Fellmann C., Stephens R., Luo J., Lowe S.W., Benes C.H.,
RA   McCormick F.;
RT   "Differential effector engagement by oncogenic KRAS.";
RL   Cell Rep. 22:1889-1902(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//